share_log

前沿生物(688221.SH)发上半年业绩,净亏损1.6亿元

Frontline Bio (688221.SH) released its performance for the first half of the year, with a net loss of 0.16 billion yuan.

Zhitong Finance ·  Aug 30 11:26

Frontier Biology (688221.SH) released its 2024 semi-annual report, with the company achieving revenue of 5 million yuan during the reporting period...

According to the 2024 semi-annual report released by Frontier Biology (688221.SH), the company achieved revenue of 51.056 million yuan during the reporting period, a year-on-year growth of 20.30%. The net loss attributable to shareholders of the listed company was 0.16 billion yuan; the net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 0.176 billion yuan; the basic loss per share was 0.43 yuan/share.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment